In-vivo pharmacological evaluation of the CB1-receptor allosteric modulator Org-27569

Thomas F Gamage, Bogna M Ignatowska-Jankowska, Jenny L Wiley, Mostafa Abdelrahman, Laurent Trembleau, Iain R Greig, Ganesh A Thakur, Ritesh Tichkule, Justin Poklis, Ruth A Ross, Roger G Pertwee, Aron H Lichtman

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Several allosteric modulators (AMs) of the CB1 receptor have been characterized in vitro, including Org27569, which enhances CB1-specific binding of [H]CP55,940, but behaves as an insurmountable CB1-receptor antagonist in several biochemical assays. Although a growing body of research has investigated the molecular actions of this unusual AM, it is unknown whether these actions translate to the whole animal. The purpose of the present study was to determine whether Org27569 would produce effects in well-established mouse behavioral assays sensitive to CB1 orthosteric agonists and antagonists. Similar to the orthosteric CB1 antagonist/inverse agonist rimonabant, Org27569 reduced food intake; however, this anorectic effect occurred independently of the CB1 receptor. Org27569 did not elicit CB1-mediated effects alone and lacked efficacy in altering antinociceptive, cataleptic, and hypothermic actions of the orthosteric agonists anandamide, CP55,940, and Δ-tetrahydrocannabinol. Moreover, it did not alter the discriminative stimulus effects of anandamide in FAAH-deficient mice or Δ-tetrahydrocannabinol in wild-type mice in the drug discrimination paradigm. These findings question the utility of Org27569 as a 'gold standard' CB1 AM and underscore the need for the development of CB1 AMs with pharmacology that translates from the molecular level to the whole animal.

Original languageEnglish
Pages (from-to)182-185
Number of pages4
JournalBehavioural Pharmacology
Volume25
Issue number2
DOIs
Publication statusPublished - Apr 2014

Fingerprint

Cannabinoid Receptor CB1
Pharmacology
rimonabant
Dronabinol
Appetite Depressants
Eating
5-chloro-3-ethyl-1H-indole-2-carboxylic acid (2-(4-piperidin-1-yl-phenyl)ethyl)amide
Research
Pharmaceutical Preparations

Cite this

Gamage, T. F., Ignatowska-Jankowska, B. M., Wiley, J. L., Abdelrahman, M., Trembleau, L., Greig, I. R., ... Lichtman, A. H. (2014). In-vivo pharmacological evaluation of the CB1-receptor allosteric modulator Org-27569. Behavioural Pharmacology, 25(2), 182-185. https://doi.org/10.1097/FBP.0000000000000027

In-vivo pharmacological evaluation of the CB1-receptor allosteric modulator Org-27569. / Gamage, Thomas F; Ignatowska-Jankowska, Bogna M; Wiley, Jenny L; Abdelrahman, Mostafa; Trembleau, Laurent; Greig, Iain R; Thakur, Ganesh A; Tichkule, Ritesh; Poklis, Justin; Ross, Ruth A; Pertwee, Roger G; Lichtman, Aron H.

In: Behavioural Pharmacology, Vol. 25, No. 2, 04.2014, p. 182-185.

Research output: Contribution to journalArticle

Gamage, TF, Ignatowska-Jankowska, BM, Wiley, JL, Abdelrahman, M, Trembleau, L, Greig, IR, Thakur, GA, Tichkule, R, Poklis, J, Ross, RA, Pertwee, RG & Lichtman, AH 2014, 'In-vivo pharmacological evaluation of the CB1-receptor allosteric modulator Org-27569', Behavioural Pharmacology, vol. 25, no. 2, pp. 182-185. https://doi.org/10.1097/FBP.0000000000000027
Gamage, Thomas F ; Ignatowska-Jankowska, Bogna M ; Wiley, Jenny L ; Abdelrahman, Mostafa ; Trembleau, Laurent ; Greig, Iain R ; Thakur, Ganesh A ; Tichkule, Ritesh ; Poklis, Justin ; Ross, Ruth A ; Pertwee, Roger G ; Lichtman, Aron H. / In-vivo pharmacological evaluation of the CB1-receptor allosteric modulator Org-27569. In: Behavioural Pharmacology. 2014 ; Vol. 25, No. 2. pp. 182-185.
@article{e77bec998641476da2403adff53f8e1d,
title = "In-vivo pharmacological evaluation of the CB1-receptor allosteric modulator Org-27569",
abstract = "Several allosteric modulators (AMs) of the CB1 receptor have been characterized in vitro, including Org27569, which enhances CB1-specific binding of [H]CP55,940, but behaves as an insurmountable CB1-receptor antagonist in several biochemical assays. Although a growing body of research has investigated the molecular actions of this unusual AM, it is unknown whether these actions translate to the whole animal. The purpose of the present study was to determine whether Org27569 would produce effects in well-established mouse behavioral assays sensitive to CB1 orthosteric agonists and antagonists. Similar to the orthosteric CB1 antagonist/inverse agonist rimonabant, Org27569 reduced food intake; however, this anorectic effect occurred independently of the CB1 receptor. Org27569 did not elicit CB1-mediated effects alone and lacked efficacy in altering antinociceptive, cataleptic, and hypothermic actions of the orthosteric agonists anandamide, CP55,940, and Δ-tetrahydrocannabinol. Moreover, it did not alter the discriminative stimulus effects of anandamide in FAAH-deficient mice or Δ-tetrahydrocannabinol in wild-type mice in the drug discrimination paradigm. These findings question the utility of Org27569 as a 'gold standard' CB1 AM and underscore the need for the development of CB1 AMs with pharmacology that translates from the molecular level to the whole animal.",
author = "Gamage, {Thomas F} and Ignatowska-Jankowska, {Bogna M} and Wiley, {Jenny L} and Mostafa Abdelrahman and Laurent Trembleau and Greig, {Iain R} and Thakur, {Ganesh A} and Ritesh Tichkule and Justin Poklis and Ross, {Ruth A} and Pertwee, {Roger G} and Lichtman, {Aron H}",
year = "2014",
month = "4",
doi = "10.1097/FBP.0000000000000027",
language = "English",
volume = "25",
pages = "182--185",
journal = "Behavioural Pharmacology",
issn = "0955-8810",
publisher = "Lippincott Williams & Wilkins",
number = "2",

}

TY - JOUR

T1 - In-vivo pharmacological evaluation of the CB1-receptor allosteric modulator Org-27569

AU - Gamage, Thomas F

AU - Ignatowska-Jankowska, Bogna M

AU - Wiley, Jenny L

AU - Abdelrahman, Mostafa

AU - Trembleau, Laurent

AU - Greig, Iain R

AU - Thakur, Ganesh A

AU - Tichkule, Ritesh

AU - Poklis, Justin

AU - Ross, Ruth A

AU - Pertwee, Roger G

AU - Lichtman, Aron H

PY - 2014/4

Y1 - 2014/4

N2 - Several allosteric modulators (AMs) of the CB1 receptor have been characterized in vitro, including Org27569, which enhances CB1-specific binding of [H]CP55,940, but behaves as an insurmountable CB1-receptor antagonist in several biochemical assays. Although a growing body of research has investigated the molecular actions of this unusual AM, it is unknown whether these actions translate to the whole animal. The purpose of the present study was to determine whether Org27569 would produce effects in well-established mouse behavioral assays sensitive to CB1 orthosteric agonists and antagonists. Similar to the orthosteric CB1 antagonist/inverse agonist rimonabant, Org27569 reduced food intake; however, this anorectic effect occurred independently of the CB1 receptor. Org27569 did not elicit CB1-mediated effects alone and lacked efficacy in altering antinociceptive, cataleptic, and hypothermic actions of the orthosteric agonists anandamide, CP55,940, and Δ-tetrahydrocannabinol. Moreover, it did not alter the discriminative stimulus effects of anandamide in FAAH-deficient mice or Δ-tetrahydrocannabinol in wild-type mice in the drug discrimination paradigm. These findings question the utility of Org27569 as a 'gold standard' CB1 AM and underscore the need for the development of CB1 AMs with pharmacology that translates from the molecular level to the whole animal.

AB - Several allosteric modulators (AMs) of the CB1 receptor have been characterized in vitro, including Org27569, which enhances CB1-specific binding of [H]CP55,940, but behaves as an insurmountable CB1-receptor antagonist in several biochemical assays. Although a growing body of research has investigated the molecular actions of this unusual AM, it is unknown whether these actions translate to the whole animal. The purpose of the present study was to determine whether Org27569 would produce effects in well-established mouse behavioral assays sensitive to CB1 orthosteric agonists and antagonists. Similar to the orthosteric CB1 antagonist/inverse agonist rimonabant, Org27569 reduced food intake; however, this anorectic effect occurred independently of the CB1 receptor. Org27569 did not elicit CB1-mediated effects alone and lacked efficacy in altering antinociceptive, cataleptic, and hypothermic actions of the orthosteric agonists anandamide, CP55,940, and Δ-tetrahydrocannabinol. Moreover, it did not alter the discriminative stimulus effects of anandamide in FAAH-deficient mice or Δ-tetrahydrocannabinol in wild-type mice in the drug discrimination paradigm. These findings question the utility of Org27569 as a 'gold standard' CB1 AM and underscore the need for the development of CB1 AMs with pharmacology that translates from the molecular level to the whole animal.

U2 - 10.1097/FBP.0000000000000027

DO - 10.1097/FBP.0000000000000027

M3 - Article

VL - 25

SP - 182

EP - 185

JO - Behavioural Pharmacology

JF - Behavioural Pharmacology

SN - 0955-8810

IS - 2

ER -